These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 22014125

  • 1. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.
    Lu H, Balakrishnan A, Howatt DA, Wu C, Charnigo R, Liau G, Cassis LA, Daugherty A.
    Br J Pharmacol; 2012 Mar; 165(6):2000-2008. PubMed ID: 22014125
    [Abstract] [Full Text] [Related]

  • 2. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
    Fraune C, Lange S, Krebs C, Hölzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelds IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G, Wenzel UO.
    Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
    [Abstract] [Full Text] [Related]

  • 3. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 4. Renin inhibition and atherosclerosis.
    Luft FC.
    Nephrol Dial Transplant; 2008 Aug; 23(8):2474-6. PubMed ID: 18430802
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice.
    Lu H, Rateri DL, Feldman DL, Charnigo RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A.
    J Clin Invest; 2008 Mar; 118(3):984-93. PubMed ID: 18274671
    [Abstract] [Full Text] [Related]

  • 9. Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques.
    Wu H, Cheng XW, Hu L, Hao CN, Hayashi M, Takeshita K, Hamrah MS, Shi GP, Kuzuya M, Murohara T.
    Atherosclerosis; 2014 Dec; 237(2):739-47. PubMed ID: 25463114
    [Abstract] [Full Text] [Related]

  • 10. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R, Frishman WH, Stier CT, Sica DA.
    Cardiol Rev; 2007 Dec; 15(5):242-56. PubMed ID: 17700383
    [Abstract] [Full Text] [Related]

  • 11. The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis.
    Parreira NA, Ramalho FS, Augusto MJ, Silva DM, Prado CM, Elias Júnior J, Rodrigues V, Ramalho LNZ.
    Exp Parasitol; 2018 Aug; 191():9-18. PubMed ID: 29890165
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM.
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [Abstract] [Full Text] [Related]

  • 13. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
    van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH.
    J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
    [Abstract] [Full Text] [Related]

  • 14. Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
    Yang J, Sun Y, Dong M, Yang X, Meng X, Niu R, Guan J, Zhang Y, Zhang C.
    Atherosclerosis; 2015 Jun; 240(2):544-9. PubMed ID: 25957120
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [Abstract] [Full Text] [Related]

  • 16. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.
    López V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Martínez D, Hernandez D.
    Transplant Proc; 2010 Oct; 42(8):2883-5. PubMed ID: 20970559
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
    Bro S, Binder CJ, Witztum JL, Olgaard K, Nielsen LB.
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1080-6. PubMed ID: 17347482
    [Abstract] [Full Text] [Related]

  • 18. Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis.
    Chen X, Lu H, Zhao M, Tashiro K, Cassis LA, Daugherty A.
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2075-80. PubMed ID: 23846498
    [Abstract] [Full Text] [Related]

  • 19. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L.
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [Abstract] [Full Text] [Related]

  • 20. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.